At One Nucleus, international connectivity is more than just a concept; it is at the core of what our members do and hence why we seek to complement that connectivity in how we support members. Whilst much of what One Nucleus delivers is done within the greater Cambridge-London region, our connectivity extends far beyond the UK. The connections can be through collaboration with peer industry membership groups such MassBio, Biocom California, LINK-J and collaborative members of the Council for European BioRegions (CEBR) or equally via our members who often have a presence…
By Tony Jones, CEO, One Nucleus
Recent weeks have been filled with varying degrees of anticipation and apprehension with regards to what UK government would start crystallising from grand election campaign gestures to actual measures and policies. After what felt like a long run of warnings of doom to the finally delivered ‘Invest 2025: the UK’s modern industrial strategy’ and ‘Autumn Budget 2024’.
There will be much written, both critical and positive, about both of the above articles I am sure where shaping the details of implementation becomes the key focus. There were a number of…
By Alicia Gailliez, Business Development Manager, One Nucleus
The theory behind belonging to a group is multifaceted, spanning many theoretical frameworks, but essentially it is important because members of the group will experience personal fulfilment and shared purpose. Take one of the most well-known theories, for example, Maslow’s Hierarchy of Needs, which suggests five key human needs that people must meet to achieve well-being, including ‘love and belonging’. This theory explains how belonging to a group and working towards a common goal can drive self-actualisation, the ability to…
A challenge for busy life science professionals seeking to build collaboration with the right contacts in a sea of potential opportunities, is navigating these waters quickly and, saving crucial time and effort. To help you find the right opportunities, One Nucleus has unveiled its new and improved One Nucleus website, designed specifically with our life science ecosystem in mind! At One Nucleus, we understand the importance of staying connected, accessing the right resources, being seen by others, and fostering growth within the life science and healthcare industry. Our revamped website aims…
It is very much recognised that success in Life Sciences, bringing innovative new treatments and diagnostics to patients, is a team game. Best in class Innovation, collaboration, services, and infrastructure are all pivotal to addressing the complex challenges of finding solutions to unmet medical need. The One Nucleus Annual Awards seek to recognise excellence across the whole Life Science ecosystem given the vital role each stakeholder plays. To see which companies were setting the standard in 2024, you can read the event report from the gala dinner.
Ensuring opportunity for everyone to…
Guest blog post by Domainex
Domainex launches a new webinar series, hosted by One Nucleus, to discuss the latest approaches and technologies that will be vital in any drug discovery programme.
Following the boom-and-bust years of Covid investment followed by economic challenges, the UK life science industry is still driving progress in drug discovery. But with the cost of medicines development continuing to soar, staying one step ahead in this competitive space is an ongoing challenge.
Domainex, an award-winning CRO based in Cambridge, UK, is adept at tackling this challenge head on, working…
By Alicia Gailliez, Business Development Manager, One Nucleus
It is well accepted that if a business wishes to attract partners or clients, advertisements in trade and technical publications in their field can be extremely effective. Aligning with content of interest and relevance to the target audience can see increased sales, product enquiries, a higher profile, trade partnerships and even potential investors. The barrier, as is often the case, is the available marketing budget, how it can be best deployed and how to make that buying decision.
Useful measurement tools including circulation…
By Alicia Gailliez, Business Development Manager, One Nucleus
CRISPR is short for “clustered regularly interspaced short palindromic repeats”. An article from The Jackson Laboratory on ‘What is CRISPR’ describes how the term makes reference to the repetitive pattern of DNA and “spacer” sequences in bacteria. It was discovered that bacteria transcribe these DNA elements to RNA upon viral infection. The RNA guides a nuclease (a protein that cleaves DNA) to the viral DNA to cut it, providing protection against the virus. The nucleases are named “Cas,” for “CRISPR-associated.”
This concept…
By Tony Jones, CEO, One Nucleus
Building on the development of the Bridge to Boston activities commenced at the One Nucleus Breakfast at BIO 2023 hosted by McDermott Will & Emery, followed by the Boston Bootcamp in April this year and the Breakfast at BIO 2024 with Mintz; One Nucleus continues to explore the opportunities to support the international investment, collaboration, and outsourcing deal flow needs of our members. Of course, the starting point for such support is the day-to-day support we offer our members locally in order to facilitate them being the best versions of themselves…
Research conducted by Pioneer Group sheds light on the current investment trends shaping the life sciences landscape, offering insights into where capital is being allocated and what it means for the sector.
The fall in venture capital investment levels over recent years has caused some concern in the real estate sector.
However, it’s important to note that 2021 witnessed a whirlwind of venture capital activity, particularly in the first and second quarters. These periods were marked by a handful of colossal investments, including landmark figures pumped into entities like CMR Surgical,…